Compare KOYN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KOYN | CBIO |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.9M | 389.7M |
| IPO Year | N/A | N/A |
| Metric | KOYN | CBIO |
|---|---|---|
| Price | $10.03 | $11.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 72.3K | ★ 163.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $8.72 |
| 52 Week High | $10.08 | $17.39 |
| Indicator | KOYN | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 48.99 |
| Support Level | $9.95 | $10.45 |
| Resistance Level | $10.05 | $13.37 |
| Average True Range (ATR) | 0.01 | 0.89 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 20.04 | 23.49 |
CSLM Digital Asset Acquisition Corp III Ltd is a blank check company that acts to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.